$EYPT

Zaderej Karen L. purchased $52K of EYPT

Zaderej Karen L. purchased 10,600 shares of EyePoint, Inc. (EYPT) at $4.93 on 2026-08-18.

Original reporting
SEC EDGAR · Zaderej Karen L.
Published Aug 18, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EYPT
Bullish
medium confidence
Mentioned
$EYPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EYPTBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 10,600 shares at $4.93 on 2026-08-18, with holdings after the trade of 49,100 shares.

02

Market read

Traders may treat the Form 4 as a small sentiment input, but it does not introduce new operating or financial information.

03

What to watch

The filing notes no 10b5-1 plan, but it still does not provide context on motivation, timing constraints, or whether the director has other concurrent transactions.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, same day as the reported purchase date

Background

The article is an SEC Form 4 insider transaction disclosure for EyePoint, Inc.

Company-level read

Ticker impact

$EYPTBullishMedium confidence
Context

EyePoint director Zaderej Karen L. bought 10,600 shares on 2026-08-18 at $4.93, totaling $52,258, per Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small versus market-moving events.

Evidence & confidence

The filing is a primary-source Form 4 and the buyer is a director, but the transaction size is relatively small and there is no accompanying company-specific news (no guidance, trial, contract, or regulatory action).

Market effects

No clear sector read-through; this is a single-company insider transaction without new clinical or regulatory information.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect near-term operational improvements.

Key entities

  • EyePoint, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Zaderej Karen L.

    Director who purchased 10,600 shares for $52,258 on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNHigh

Why AZN, VSXY, EYPT Stocks Are Moving Premarket Today

AstraZeneca (AZN) shares rose 1.8% premarket after Oracle (ORCL) announced a non-binding AI collaboration. Victoria’s Secret (VSXY) gained 1% following a Barclays price target increase to $112. EyePoint Pharmaceuticals (EYPT) fell 4.4% after JPMorgan downgraded it to 'Underweight' due to a clinical trial setback.

$EYPTMedAI 8/10

JPMorgan downgrades EyePoint stock rating on trial failures

JPMorgan downgraded EyePoint Inc. (EYPT) to Underweight after its LUCIA trial failed to meet the primary endpoint. The company will focus on diabetic macular edema trials, with data expected in 2027. Multiple analysts downgraded EYPT, citing trial setbacks and cash burn concerns. The stock has fallen 85.67% in a week, with a market cap of $37.93 million.

$EYPTHighAI 8/10

Jefferies downgrades Eyepoint stock rating on trial miss

Jefferies downgraded EyePoint Inc. (NASDAQ:EYPT) to Hold, cutting its price target to $1.00 from $8.00. The stock fell 86% to $0.45 after its Phase 3 LUCIA study missed its primary endpoint. The company has $118 million in cash but faces cash burn and extended timelines for other programs. Multiple analysts have downgraded the stock due to trial setbacks.